To explore the value of CEA, cy211, NSE and CA125 in the diagnosis of lung cancer.

140 patients with lung cancer admitted to our hospital from October 2018 to June 2019 were selected as the lung cancer group, and 136 patients with benign lung disease admitted to our hospital during the same period were selected as the control group. The serum CEA, cy211, NSE and CA125 levels of the two groups were compared, and the working characteristic curve (ROC) of the subjects was drawn to analyze the diagnostic value of each index for lung cancer, and the area under the curve (AUC), the best boundary value, the corresponding sensitivity and specificity were determined. With pathological diagnosis as the gold standard, Kappa test was used to analyze the consistency between the combined diagnosis of lung cancer and pathological diagnosis of the four indicators, as well as the sensitivity, specificity, Coincidence rate, positive predictive value and negative predictive value.

Serum CEA, CY211, NSE and CA125 levels in lung cancer group were significantly higher than those in control group (P<0.05). The AUC of serum CEA, cy211, NSE and CA125 were 0.773, 0.762, 0.753 and 0.801, respectively. The AUC of combined diagnosis was 0.906.When CEA>7.965 ng/ml, cy211>7.960 ng/ml, NSE>28.025 ng/ml, CA125>22.065 U/ml, the higher the risk of lung cancer. Pathological diagnosis was taken as the gold standard, suggesting that the sensitivity, specificity and coincidence rate of the combined diagnosis of lung cancer with the four indicators were 90.00%, 91.18% and 90.58%, respectively. The positive predictive value and negative predictive value were 90.00% and 91.18% respectively, and the consistency between them and the pathological diagnosis by Kappa test was 0.812 (highly consistent).

Compared with patients with benign lung diseases, serum CEA, CY211, NSE and CA125 in patients with lung cancer were significantly increased, and all the four patients had certain value in lung cancer diagnosis.